Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2019

01-01-2019 | Original paper

Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk

Authors: Rosie Cornish, Anne Cathrine Staff, Andy Boyd, Debbie A. Lawlor, Steinar Tretli, Gary Bradwin, Thomas F. McElrath, Marianne Hyer, Robert N. Hoover, Rebecca Troisi

Published in: Cancer Causes & Control | Issue 1/2019

Login to get access

Abstract

Purpose

Breast cancer risk associated with pregnancy characteristics may be mediated by maternal hormones or angiogenic factors.

Methods

We conducted a prospective breast cancer case-control study among women in the Avon Longitudinal Study of Parents and Children (ALSPAC) and Norwegian Mother and Child Cohort Study (MoBa) related to maternal pregnancy prolactin (n = 254 cases and 374 controls), placental growth factor (PlGF, n = 252 and 371), soluble fms-like tyrosine kinase-1 (sFlt-1, n = 118 and 240) and steroid hormone concentrations (ALSPAC only, n = 173 and 171). Odds ratios (OR) and 95% confidence intervals (CI) for a 1 SD change in analytes were estimated using unconditional logistic regression with matching factors (cohort, mother’s birth year, serum/plasma, blood collection timing) and gestational age.

Results

Breast cancer ORs (95% CI) were 0.85 (0.51–1.43) for estradiol, 0.86 (0.67–1.09) for testosterone, 0.89 (0.71–1.13) for androstenedione, 0.97 (0.71–1.34) for hCG, 0.93 (0.75, 1.15) for prolactin, 1.00 (0.78–1.27) for PlGF and 1.91 (1.00–3.65 ALSPAC) and 0.94 (0.73–1.21 MoBa) for sFlt-1, and were similar adjusting for potential confounders. Results were similar by blood collection timing, parity, age at first birth or diagnosis, and time between pregnancy and diagnosis.

Conclusion

These data do not provide strong evidence of associations between maternal hormones or angiogenic factors with subsequent maternal breast cancer risk.
Appendix
Available only for authorised users
Literature
1.
Medina D (2005) Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12:483–495CrossRef
2.
Schedin P (2006) Pregnancy-associated breast cancer and metastasis. Nat Rev Cancer 6:281–291CrossRef
3.
Key T, Appleby P, Barnes I, Reeves G, Endogenous, Hormones & Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616CrossRef
4.
Richardson BE, Hulka BS, Peck JL, Hughes CL, van den Berg BJ, Christianson RE, Calvin JA (1998) Levels of maternal serum alpha-fetoprotein (AFP) in pregnant women and subsequent breast cancer risk. Am J Epidemiol 148:719–727CrossRef
5.
Melbye M, Wohlfahrt J, Lei U, Nørgaard-Pedersen B, Mouridsen HT, Lambe M, Michels KB (2000) Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 92:1001–1005CrossRef
6.
Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE (2002) Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev 11:361–368PubMed
7.
Lukanova A, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K, Wulff M, Arslan AA, Afanasyeva Y, Johansson R, Lenner P, Hallmans G et al (2006) Insulin-like growth factor I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 15:2489–2493CrossRef
8.
Lukanova A, Andersson R, Wulff M, Zeleniuch-Jacquotte A, Grankvist K, Dossus L, Afanasyeva Y, Johansson R, Arslan AA, Lenner P et al (2008) Human chorionic gonadotropin and alpha-fetoprotein concentrations in pregnancy and maternal risk of breast cancer: a nested case-control study. Am J Epidemiol 168:1284–1291CrossRef
9.
Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, Husing A, Kaaks R, Koskela P, Grankvist K et al (2012) Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer. Int J Cancer 130:910–920CrossRef
10.
Vatten LJ, Romundstad PR, Jenum PA, Eskild A (2009) Angiogenic balance in pregnancy and subsequent breast cancer risk and survival: a population study. Cancer Epidemiol Biomark Prev 18:2074–2078CrossRef
11.
Jeffreys M, Northstone K, Holly J, Emmett P, Gunnell D (2011) Levels of insulin-like growth factor during pregnancy and maternal cancer risk: a nested case-control study. Cancer Causes Control 22:945–953CrossRef
12.
Toniolo P, Grankvist K, Wulff M, Chen T, Johansson R, Schock H, Lenner P, Hallmans G, Lehtinen M, Kaaks R et al (2010) Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. Cancer Res 70:6779–6786CrossRef
13.
Toriola AT, Lundin E, Schock H, Grankvist K, Pukkala E, Chen T, Zeleniuch-Jacquotte A, Toniolo P, Lehtinen M, Surcel HM et al (2011) Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer. Cancer Epidemiol Biomark Prev 20:1798–1801CrossRef
14.
Toriola AT, Tolockiene E, Schock H, Surcel HM, Zeleniuch-Jacquotte A, Wadell G, Toniolo P, Lundin E, Grankvist K, Lukanova A (2014) Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer. Future Oncol 10:377–384CrossRef
15.
Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Grankvist K et al (2014) Early pregnancy sex steroids and maternal breast cancer: a nested case-control study. Cancer Res 74:6958–6967CrossRef
16.
Fortner RT, Tolockiene E, Schock H, Oda H, Lakso H, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K et al (2017) Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden maternity cohort. Breast Cancer Res 19:82CrossRef
17.
Cohn BA, Cirillo PM, Hopper BR, Siiteri PK (2017) Third trimester estrogens and maternal breast cancer: prospective evidence. J Clin Endocrinol Metab 102:3739–3748CrossRef
18.
Troisi R, Weiss HA, Hoover RN, Potischman N, Swanson CA, Brogan DR, Coates RJ, Gammon MD, Malone KE, Daling JR et al (1998) Pregnancy characteristics and maternal risk of breast cancer. Epidemiology 9:641–647CrossRef
19.
Innes KE, Byers TE (1999) Preeclampsia and breast cancer risk. Epidemiology 10:722–732CrossRef
20.
Vatten LJ, Romundstad PR, Trichopoulos D, Skjærven R (2002) Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 87:971–973CrossRef
21.
Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005) Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57:1R–7RCrossRef
22.
Aagaard-Tillery KM, Stoddard GJ, Holmgren C, Lacoursiere DY, Fraser A, Mineau GP, Varner MW (2006) Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 195:691–699CrossRef
23.
Troisi R, Braekke K, Harsem NK, Hyer M, Hoover RN, Staff AC (2008) Blood pressure augmentation and maternal circulating concentrations of angiogenic factors at delivery in preeclamptic and uncomplicated pregnancies. Am J Obstet Gynecol 199:653.e1–653.e10CrossRef
24.
Redman CW, Staff AC (2015) Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol 213:S9.e1–S9.e11CrossRef
25.
Boyd A, Golding J, Macleod J, Lawlor DA, Fraser A, Henderson J, Molloy L, Ness A, Ring S, Davey Smith G (2013) Cohort profile: the ‘children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children. Int J Epidemiol 42:111–127CrossRef
26.
Fraser A, Macdonald-Wallis C, Tilling K, Boyd A, Golding J, Davey Smith G, Henderson J, Macleod J, Molloy L, Ness A et al (2013) Cohort profile: the Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. Int J Epidemiol 42:97–110CrossRef
27.
Magnus P, Birke C, Vejrup K, Haugan A, Alsaker E, Daltveit AK, Handal M, Haugen M, Hoiseth G, Knudsen GP et al (2016) Cohort profile update: the Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol 45:382–388CrossRef
28.
Mabie J, Riley T, Marcus PM, Black A, Rozjabek H, Yu K, Young M, Austin J, Rathmell J, Williams C et al (2015) Data processing and analytic support in the PLCO cancer screening trial. Rev Recent Clin Trials 10:233–237CrossRef
29.
Troisi R, Ganmaa D, dos Santos Silva I, Davaalkham D, Rosenberg PS, Rich-Edwards J, Frasier L, Houghton L, Janes C, Stanczyk F et al (2014) The role of hormones in the differences in the incidence of breast cancer between Mongolia and the United Kingdom. PLoS ONE 9:e114455CrossRef
30.
Paltiel L, Haugan A, Skjerden T, Harbak K, Bækken S, Stensrud NK, Knudsen GP, Magnus P (2014) The biobank of the Norwegian Mother and Child Cohort Study—present status. Nor J Epidemiol 24:29–35CrossRef
31.
Royston P, Ambler G, Sauerbrei W (1999) The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 28:964–974CrossRef
32.
Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso H, Tanner M, Kallio R, Joensuu H, Korpela J et al (2017) Human chorionic gonadotropin does not correlate with risk for maternal breast cancer: results from the finnish maternity cohort. Cancer Res 77:134–141CrossRef
33.
Wang M, Wu X, Chai F, Zhang Y, Jiang J (2016) Plasma prolactin and breast cancer risk: a meta-analysis. Sci Rep 6:25998CrossRef
34.
Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP et al (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672–683CrossRef
35.
Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso H-Å, Idahl A, Lehtinen M, Surcel H-M, Fortner RT (2016) Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study. BMC Pregnancy Childbirth 16:146CrossRef
36.
Neville MC, McFadden TB, Forsyth I (2002) Hormonal regulation of mammary differentiation and milk secretion. J Mamm Gland Biol Neoplasia 7:49–66CrossRef
37.
38.
Fuhrman BJ, Xu X, Falk RT, Hankinson SE, Veenstra TD, Keefer LK, Ziegler RG (2010) Stability of 15 estrogens and estrogen metabolites in urine samples under processing and storage conditions typically used in epidemiologic studies. Int J Biol Mark 25:185–194CrossRef
Metadata
Title
Maternal reproductive hormones and angiogenic factors in pregnancy and subsequent breast cancer risk
Authors
Rosie Cornish
Anne Cathrine Staff
Andy Boyd
Debbie A. Lawlor
Steinar Tretli
Gary Bradwin
Thomas F. McElrath
Marianne Hyer
Robert N. Hoover
Rebecca Troisi
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 1/2019
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-018-1100-6

Other articles of this Issue 1/2019

Cancer Causes & Control 1/2019 Go to the issue

Original paper

Concordance of cancer registry and self-reported race, ethnicity, and cancer type: a report from the American Cancer Society’s studies of cancer survivors

Original paper

Potential protein markers for breast cancer recurrence: a retrospective cohort study

Original paper

Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status

Original paper

Habitual recreational physical activity is associated with significantly improved survival in cancer patients: evidence from the Roswell Park Data Bank and BioRepository

Original paper

Pre- and perinatal factors and incidence of breast cancer in the Black Women’s Health Study

Original paper

Interplay between exercise and BMI; results from an equal access, racially diverse biopsy study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits